For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Elucid Bioimaging Inc.

USPTO Granted Patents = 39

EPO Patents = 1

Trademarks = 10

Forward Citations = 967

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Andrew J Buckler (39 out of 46 patents)

Xiaonan Ma (22 out of 23 patents)

David Seungwon Paik (21 out of 34 patents)

4. Keith A Moulton (21 out of 24 patents)

5. Kjell Johnson (20 out of 21 patents)

6. Mark A Buckler (13 out of 17 patents)

7. Vladimir Valtchinov (10 out of 11 patents)

8. Matthew Phillips (8 out of 8 patents)

9. Ulf Hedin (7 out of 7 patents)

10. Ljubica Matic (7 out of 7 patents)

11. Changguo Ji (4 out of 4 patents)

12. Murali Ayyapillai (4 out of 4 patents)

13. Mary E Buckler (2 out of 2 patents)

14. Anant Madabhushi (1 out of 107 patents)

15. Lawrence Martell (1 out of 1 patent)

39 patents: Sort by Forward Citations

1. 12236595 - Characterizing permeability, neovascularization, necrosis, collagen breakdown, or inflammation (2025-02-25),

2. 12229957 - Systems and methods for diagnostics for management of cardiovascular disease patients (2025-02-18),

3. 12159406 - Determining biological properties of atherosclerotic plaque, coronary artery disease, or vasculopathy (2024-12-03),

4. 12154321 - Structured representations for interpretable machine learning applications in medical imaging (2024-11-26),

5. 12141975 - Myocardial ischemia prediction (2024-11-12),

6. 12136214 - Non-invasive imaging to inform patient care (2024-11-05),

7. 12131472 - Non-invasive imaging to determine health and disease (2024-10-29),

8. 12131471 - Longitudinal change measures for optimizing patient care (2024-10-29),

9. 12125572 - Determining likely response to anti-inflammatory and pro-resolving therapies for cardiovascular disease non-invasively (2024-10-22),

10. 12125571 - Determining likely response to glycemic treatment for cardiovascular disease non-invasively (2024-10-22),

11. 12118694 - Progressive exploitation of multi-energy and photon counting modalities (2024-10-15),

12. 12106477 - Segmenting permeability, neovascularization, necrosis, collagen breakdown, or inflammation to characterize atherosclerotic plaque, coronary artery disease, or vasculopathy (2024-10-01),

13. 12100149 - Determining likely response to combination therapies for cardiovascular disease non-invasively (2024-09-24),

14. 12073561 - Multiscale modeling to determine molecular profiles from radiology (2024-08-27),

15. 12045983 - Functional measures of stenosis significance (2024-07-23),

Elucid Bioimaging Inc. is a leading medical imaging company that develops advanced technology solutions for improved disease diagnosis and treatment. With a focus on molecular imaging and artificial intelligence, their innovative products enable healthcare professionals to make more accurate and personalized decisions. Through their cutting-edge research and development, Elucid Bioimaging is dedicated to advancing the field of medical imaging and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

39 Patents

#61 in Boston, MA

#497 in Massachusetts

#8,545 in US

#16,953 in the World

Boston, MA, United States of America

Elucid Bioimaging Inc.

Forward Citations = 967

20 inventors:

Andrew J Buckler (39 out of 46 patents)

Xiaonan Ma (22 out of 23 patents)

David Seungwon Paik (21 out of 34 patents)

4. Keith A Moulton (21 out of 24 patents)

5. Kjell Johnson (20 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…